K. Sitek-Ziółkowska

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis

M. Weinblatt, J. Vencovský, J. Choe, 2017, Arthritis & rheumatology.

FRI0161 Sustained Efficacy and Comparable Safety and Immunogenicity after Transition To SB5 (An Adalimumab Biosimilar) vs Continuation of The Adalimumab Reference Product in Patients with Rheumatoid Arthritis: Result of Phase III Study

V. Zhdan, M. Weinblatt, J. Jaworski, 2016 .